Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Patients with locally advanced (stage III) breast cancer (LABC) are characterized by a
significantly worse prognosis compared to patients with primarily operable breast cancer.
While neoadjuvant chemotherapy has been the first choice in this situation for several
decades, recent evidence suggests that some patients may experience an extraordinary effect
from neoadjuvant endocrine treatments involving aromatase inhibitors as monotherapy or in
modern drug combinations.Selected LABC patients admitted for treatment will be offered
combination therapy including letrozole and ribociclib. The overall goal of the project is to
improve understanding of tumor responses and resistance in patients suffering from
ER-positive/HER-2 negative locally advanced breast cancer, focusing on the role of the immune
system including the gut microbiome.